ClinVar Miner

Submissions for variant NM_000371.4(TTR):c.220G>C (p.Glu74Gln)

dbSNP: rs1555631393
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Athena Diagnostics RCV000518274 SCV000616211 uncertain significance not specified 2017-04-10 criteria provided, single submitter clinical testing
Invitae RCV001857934 SCV002234183 pathogenic Familial amyloid neuropathy 2021-09-08 criteria provided, single submitter clinical testing For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Glu74 amino acid residue in TTR. Other variant(s) that disrupt this residue have been determined to be pathogenic (Invitae). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt TTR protein function. ClinVar contains an entry for this variant (Variation ID: 448842). This variant is also known as Glu54Gln. This missense change has been observed in individual(s) with hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) (PMID: 25044787, 27519456, 31718691, 32000831). This variant is not present in population databases (ExAC no frequency). This sequence change replaces glutamic acid with glutamine at codon 74 of the TTR protein (p.Glu74Gln). The glutamic acid residue is highly conserved and there is a small physicochemical difference between glutamic acid and glutamine.
Ambry Genetics RCV002431479 SCV002729588 likely pathogenic Cardiovascular phenotype 2019-02-01 criteria provided, single submitter clinical testing The p.E74Q variant (also known as c.220G>C and E54Q), located in coding exon 3 of the TTR gene, results from a G to C substitution at nucleotide position 220. The glutamic acid at codon 74 is replaced by glutamine, an amino acid with highly similar properties. This variant was reported in two individuals with restrictive cardiomyopathy, biopsies documenting the presence of amyloid via Congo red staining, and a family history of a parent with cardiomyopathy. One individual also had progressive peripheral sensory motor polyneuropathy and autonomic dysfunction while the second individual had carpal tunnel syndrome; her parent with cardiomyopathy also had severe sensorimotor neuropathy (Rowczenio DM et al. Hum. Mutat., 2014 Sep;35:E2403-12). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.